Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis. APEX Part A testing every 3- or 6-month maintenance dosing showed significant improvement over the standard of care, with a 52-week readout anticipated in 1H 2026. Driven by strong enrollment, APEX Phase 2 Part B readout has been accelerated to mid-2026. First patient dosed in Phase 1b head-to-head trial of APG279 (IL-13 + OX40L) vs. DUPIXENT in atopic dermatitis, readout expected in 2H 2026. The company has $621.2 million in cash, cash equivalents, and marketable securities to support runway into Q1 2028.

Apogee Therapeutics, Inc. reported positive 16-week data from APEX Phase 2 Part A, demonstrating APG777’s potential as a best-in-class monotherapy. APG777 met primary endpoints with significant EASI reduction and showed well-tolerated safety profile. The APEX Part A maintenance phase is ongoing, testing dosing every 3- and 6-months to support long-term disease control. APEX Part B testing three doses of APG777 versus placebo has accelerated readout timing to mid-2026.

Apogee also announced the first patient dosed in a Phase 1b head-to-head trial of APG279 (APG777 + APG990) against DUPIXENT for atopic dermatitis, with readout expected in the second half of 2026. Progress continues in the combination approach of APG777 + APG333, with data from a Phase 1 trial of APG333 in healthy volunteers expected in the fourth quarter of 2025.

In their second quarter 2025 financial results, Apogee reported $621.2 million in cash, cash equivalents, and marketable securities as of June 30, 2025, to fund operations into Q1 2028. Research and development expenses increased due to further development of APG777, while general and administrative expenses increased with business expansion. The net loss for the quarter was $66.1 million, reflecting higher expenses compared to the same period in 2024.

Read more at GlobeNewswire: Apogee Therapeutics Provides Pipeline Progress and Reports